期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人非小细胞肺癌与外周血淋巴细胞表达ERCC1的相关性研究 被引量：2

ERCC1 expression in peripheral blood lymphocytes and non-small cell lung cancer
下载PDF
导出
摘要 目的探讨切除修复交叉互补基因1(excision repair cross-complementation group 1,ERCC1)在人非小细胞肺癌(non-small cell lung cancer NSCLC)癌组织和外周血淋巴细胞(peripheral blood lymphocyte,PBL)中的表达及其相关性,以期建立临床实用简便的肿瘤学指标。方法采用间接二步法免疫荧光化学染色检测47例Ⅱ期、Ⅲ期NSCLC患者癌组织和PBL中ERCC1的表达及健康人PBL中ERCC1的表达。结果ERCC1在癌组织、NSCLC患者PBL和健康人PBL中的表达分别为53.19%(25/47)、48.94%(23/47)和20%(4/20),其中癌组织的ERCC1表达与NSCLC患者PBL的表达呈正相关,20例健康人PBL的ERCC1表达阳性率显著低于NSCLC患者。ERCC1的表达与临床病理类型无关。结论检测NSCLC患者PBL的ERCC1表达可间接反应癌组织的ERCC1表达状况。 Objective To explore the correlation of the expression of excision repai r cross-complementation group 1 （ERCC1） with non-small cell lung cancer （NSCLC） tissues and peripheral blood lymphocytes （PBLs）. Methods ERCC1 expressions in specimens and PBLs from 47 patients with Stage Ⅱ and Ⅲ NSCLC and healthy PBLs were detected with double immunofluorescence staining. Results The positive expression rates of ERCC1 were 53. 19% , 48.94% , and 20% in carcinoma tissues, PBLs of NSCLC, and PBLs of healthy people, respectively. The expression rate of ERCC1 in carcinoma tissues was higher than that in PBLs of healthy people （P 〈 0.05 ） and positively correlated with that in PBLs of the patients. Conclusion The expression of ERCC1 in PBLs of NSCLC patients can indirectly represent ERCC1 expression in carcinoma tissues.
作者 郝萍 赵伟鹏 刁鑫伟 王卫东 关华军 胡义德 陈正堂
机构地区 第三军医大学新桥医院全军肿瘤研究所
出处 《第三军医大学学报》 CAS CSCD 北大核心 2009年第12期1201-1204,共4页 Journal of Third Military Medical University
关键词 切除修复交叉互补基因1 非小细胞肺癌 外周血淋巴细胞 excision repair cross-eomplementation group 1 non-small cell lung cancer peripheral blood lymphocyte
分类号 R331.144 [医药卫生—人体生理学] R730.43 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Altaha R,Liang X,Yu J J,et al.Excision repair cross complementing-group 1:gene expression and platinum resistance[J].Int J Mol Med,2004,14(6):959 -970.
  • 2Wachters F M,Wong L S,TimensW,et al.ERCC1,hRad51,and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy[J].Lung Cancer,2005,50(2):211-219.
  • 3Sanies C,Haura E B,Roig B,et al.Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer[J].Pharmacogenomics,2002,3(6):763 -780.
  • 4Rabik C A,Dolan M E.Molecular mechanisms of resistance and toxicity associated with platinating agents[J].Cancer Treat Rev,2007,33(1):9-23.
  • 5Niedernhofer L J,Odijk H,Budzowska M,et al.The structure-specific endonuclease Erccl-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks[J].Mol Cell Biol,2004,24(13):5776-5787.
  • 6Jaspers N G,Raams A,Silengo M C,et al.First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure[J].Am J Hum Genet,2007,80(3):457-466.
  • 7Reed E,Dabholkar M,Thornton K,et al.Evidence for in the appearance of mRN As of nucleotide excision repair genes,in human ovarian cancer tissues[J].Oncol Rep,2000,7(5):1123-1128.
  • 8Shirota Y,Stoehlmacher J,Brabender J,et al.ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy[J].J Clin Oncol,2001,19(5):4298-4304.
  • 9Warnecke-Eberz U,Metzger R,Miyazono F,et al.High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer[J].Clin Cancer Res,2004,10(11):3794-3799.
  • 10Ceppi P,Volante M,Novello S,et al.ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine[J].Ann Oncol,2006,17(12):1818-1825.

二级参考文献13

  • 1Kosmidis P. Chemotherapy in NSCLC : historical review [ J ].Lung Cancer,2002,38( S3 ) : 19-22.
  • 2Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging[ J ]. Chest, 1997,111 : 1718-1723.
  • 3Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer[ J]. N Engl J Med,2004 ,350 :351-360.
  • 4Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer[J]. Cancer Epidermal Biomarkers Prey, 2005,14 ( 2 ) : 491-496.
  • 5Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer [ J ]. Clin Cancer Res ,2002,8:2286-2291.
  • 6Wachters FM, Wong LS, Timens W, et al. ERCC1, hRad51,and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy[J]. Lung Cancer,2005,50(2) :211-219.
  • 7Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small-cell lung cancer[ J ]. Chest,2005,127 : 978-983.
  • 8Laskin JJ. Adjuvant chemotherapy for non-small-cell lung cancer: the new standard of care [ J ]. Future Oncol,2005,1 ( 5 ) :619-623.
  • 9van Duin M, de Wit J, Odijk .H, et al. Molecular characterization of the human excision repair gene ERCC-1 :cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10[ J ]. Cell, 1986,44 : 913-923.
  • 10Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy[ J ]. J Clin Oncol,2001,19:4298-4304.

共引文献22

同被引文献30

  • 1Wei B, Chen L, Li R, et al. Stem cells in gastrointestinal cancers: a matter of choice in cell fate determination[ J]. Expert Rev Anticancer Ther, 2010, 10 (10) : 1621 -1633.
  • 2Wang F, Wang F, Zou Z, et al. Active deformation of apoptotic intestinal epithelial cells with adhesion-restricted polarity contributes to apoptotic clearance[J]. Lab Invest, 2011, 91(3): 462-471.
  • 3Talos F, Moll U M. Role of the p53 family in stabilizing the genome and preventing polyploidization[ J ]. Adv Exp Med Biol, 2010, 676 : 73 -91.
  • 4Chow J, Poon R Y. DNA damage and polyploidization [ J ]. Adv Exp Med Biol, 2010, 676:57-71.
  • 5Gudkov A V, Komarova E A. Pathologies associated with the p53 re- sponse[J]. Cold Spring Harb Perspect Biol, 2010, 2(7) : a001180.
  • 6Lavon I, Fuchs D, Zrihan D, et al. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6) -methylguanine-DNA-methyltransferase [ J ]. Cancer Res, 2007, 67(18) : 8952 -g959.
  • 7Tomasini R, Samir A A, Cartier A, et al. TP53INPls and home- odomam-mteractmg protein kinase-2 ( HIPK2 ) are partners in regula- ting p53 aetivity[ J ]. J Biol Chem, 2003, 278 (39) : 37722 - 37729.
  • 8Gommeaux J, Cano C, Garcia S, et al. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1[J]. Mol Cell Biol, 2007, 27(6) : 2215 - 2225.
  • 9Kaina B, Christmann M, Naumann S, et al. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by al- kylating agents [ J]. DNA Repair ( Amst), 2007, 6 ( 8 ) : 1079 - 1099.
  • 10Schonn I, Hennesen J, Dartsch D C. Ku70 and Rad51 vary in their importance for the repair of doxorubicin-versus etoposide-induced DNA damage[J]. Apoptosis, 2011, 16 (4) : 359 -369.

引证文献2

二级引证文献6

第三军医大学学报
2009年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部